Zoetis (NYSE:ZTS) Hits New 12-Month Low – Here’s Why

Zoetis Inc. (NYSE:ZTS) reached a new 52-week low on Thursday . The company traded as low as $115.23 and last traded at $115.25, with a volume of 3912442 shares traded. The stock had previously closed at $119.79.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Stifel Nicolaus reduced their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. KeyCorp started coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research note on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $152.91.

Zoetis Stock Down 3.8%

The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The business has a 50-day simple moving average of $125.75 and a 200-day simple moving average of $132.31. The stock has a market cap of $48.65 billion, a P/E ratio of 19.14, a PEG ratio of 1.84 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Institutional Investors Weigh In On Zoetis

A number of institutional investors have recently added to or reduced their stakes in ZTS. Meadowbrook Advisors Group LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $341,000. PeakShares LLC bought a new position in Zoetis in the fourth quarter worth $176,000. Hsbc Holdings PLC boosted its stake in Zoetis by 18.8% during the fourth quarter. Hsbc Holdings PLC now owns 1,324,110 shares of the company’s stock worth $166,585,000 after buying an additional 209,897 shares in the last quarter. Employees Provident Fund Board bought a new stake in Zoetis in the 4th quarter valued at $193,402,000. Finally, EJMK Ventures LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $250,000. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.